EGIS 7229Alternative Names: S 21407
Latest Information Update: 15 Aug 2007
At a glance
- Originator Egis Pharmaceuticals; Servier
- Developer Egis Pharmaceuticals
- Class Antiarrhythmics
- Mechanism of Action Potassium channel antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Arrhythmias